Malaria resistance to two first-line anti-malarial drugs has spread rapidly from Cambodia to neighbouring countries in Southeast Asia, according to a study published in The Lancet Infectious Diseases journal.
Researchers from the Wellcome Sanger Institute and University of Oxford in the UK found that descendants of one multi-drug resistant malaria strain are replacing the local parasite populations in Vietnam, Laos, and northeastern Thailand. The team, including researchers from Mahidol University in Bangkok, also found that the resistant strain has picked up additional new genetic changes, which may be enhancing resistance even further.
The study reveals the importance of ongoing genomic surveillance to inform public health malaria control strategies, researchers said. Global efforts to eliminate malaria could be threatened by any delays in detecting and acting on the spread of resistance, they said.
Malaria is caused by Plasmodium parasites which are spread through mosquito bites. The World Health Organization estimates that nearly 220 million people were infected in 2017, causing at least 400,000 deaths, with children under the age of five in sub-Saharan Africa at most risk, researchers said.
Malaria can be treated when caught early enough, but the parasite is becoming resistant to anti-malarial drugs in many areas, especially Southeast Asia, putting elimination efforts at risk. Over the last decade, the first-line treatment for malaria in many areas of Asia has been a combination of two powerful antimalarial drugs – dihydroartemisinin and piperaquine – otherwise known as DHA-PPQ.
However, a previous study identified a strain of malaria that had become resistant to this treatment. Researchers found that this resistant strain, named KEL1/PLA1, because of its combination of genetic mutations that cause resistance, had spread across Cambodia under the radar between 2007 and 2013.
This highlighted an urgent need to follow up and determine how far this resistance had then spread and if it had evolved further, and eventually understand which drugs would work against current malaria parasites in Southeast Asia. The team sequenced and analysed the DNA of 1,673 Plasmodium falciparum parasites, taken from the blood of malaria patients between 2008 and 2018.
Their analysis, focusing on the KEL1 and PLA1 gene variants, revealed that the situation had got much worse after 2013. The multidrug-resistant KEL1/PLA1 parasites had spread internationally, in some regions making up more than 80 per cent of the parasites analysed.
“We discovered that the multi-drug resistant KEL1/PLA1 malaria strain had spread aggressively, replacing local malaria parasites, and had become the dominant strain in Vietnam, Laos and northeastern Thailand,” said Roberto Amato, from the Wellcome Sanger Institute.
“Our large-scale genomic approach demonstrates how surveillance can provide crucial information to malaria control programmes, supporting them in evaluating available treatment options,” Amato said. The spread is likely to have occurred because resistant parasites had an evolutionary advantage, as DHA-PPQ was the first-line treatment in most of these areas.
This killed other malaria strains but was less effective against KEL1/PLA1 malaria. The researchers discovered that not only had this resistant strain spread geographically, but it had evolved and picked up new mutations in the chloroquine resistance transporter gene (CRT).